Kyle Doherty

Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.

The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

The NCCN has published the first set of treatment recommendations for neuroblastoma.

Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.

The NCCN Breast Cancer Panel has included goserelin at 2 dosing schedules as a method for ovarian function suppression in their updated guidelines.

The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Investigators have developed a machine learning algorithm that could eventually facilitate earlier cancer detection via smaller blood draws.

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

A sBLA seeking the approval of D-VRd for transplant-eligible patients with newly diagnosed multiple myeloma was submitted to the FDA.

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

The FDA has called to add a class-wide boxed warning for CAR T-cell therapies to alert patients of the risk of developing secondary T-cell malignancies.

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.

Olverembatinib has been added to the NCCN's latest 2024 guidelines for management of chronic myeloid leukemia.

Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.

Tampa General Hospital Cancer Institute has experienced much growth since its establishment, in terms of attracting talent and expanding their footprint.

Amit Mahipal, MD, discusses data on camrelizumab plus rivoceranib in advanced HCC and the phase 3 CARES-310 trial, which is currently enrolling patients.

GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

Charles Swanton, FRCP, BSc, PhD, has a craving to understand cancer’s evolution, and his list of achievements can prove it.

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.